To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
LENZI, MARCO;
2012
Abstract
To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
